
Drug Lag for Inflammatory Bowel Disease Treatments in the East and West
Author(s) -
Shinji Okabayashi,
Taku Kobayashi,
Toshifumi Hibi
Publication year - 2018
Publication title -
inflammatory intestinal diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9403
pISSN - 2296-9365
DOI - 10.1159/000491878
Subject(s) - ulcerative colitis , medicine , inflammatory bowel disease , drug , european union , disease , lag time , pharmacology , biology , biological system , business , economic policy
Inflammatory bowel disease (IBD), though historically common in the West, is now increasingly prevalent in industrializing countries. A simultaneous dramatic increase in IBD drug options has enabled most patients to achieve remission. Nevertheless, worldwide disparities in the approval of IBD drugs, or "drug lag", remain problematic.